Galmed Pharmaceuticals Ltd (NASDAQ: GLMD)’s stock price has increased by 22.24 compared to its previous closing price of 1.57. However, the company has seen a 37.08% increase in its stock price over the last five trading sessions. prnewswire.com reported 2025-04-28 that The proprietary Self-Emulsifying Drug Delivery System (SEDDS) formulation in form of orally dispersible films allows absorption of sublingually administrated peptides such as GLP-1 (Semaglutide, Liraglutide etc.). The new formulation is expected to offer alternatives to both approved injectable semaglutide (Ozempic© and Wegovy©) and oral form (Rybelsus©), providing a non-invasive route that allows the medication to enter the bloodstream through the oral mucous membranes.
Is It Worth Investing in Galmed Pharmaceuticals Ltd (NASDAQ: GLMD) Right Now?
Additionally, the 36-month beta value for GLMD is 0.45. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 1 rating it as “hold,” and 0 rating it as “sell.”
The public float for GLMD is 2.22M and currently, short sellers hold a 4.34% ratio of that float. The average trading volume of GLMD on April 28, 2025 was 867.59K shares.
GLMD’s Market Performance
GLMD stock saw an increase of 37.08% in the past week, with a monthly gain of 14.23% and a quarterly increase of -32.90%. The volatility ratio for the week is 8.18%, and the volatility levels for the last 30 days are 11.88% for Galmed Pharmaceuticals Ltd (GLMD). The simple moving average for the last 20 days is 33.37% for GLMD stock, with a simple moving average of -40.61% for the last 200 days.
Analysts’ Opinion of GLMD
Many brokerage firms have already submitted their reports for GLMD stocks, with B. Riley FBR repeating the rating for GLMD by listing it as a “Neutral.” The predicted price for GLMD in the upcoming period, according to B. Riley FBR is $8 based on the research report published on May 22, 2020 of the previous year 2020.
Craig Hallum, on the other hand, stated in their research note that they expect to see GLMD reach a price target of $18. The rating they have provided for GLMD stocks is “Buy” according to the report published on February 04th, 2020.
Cantor Fitzgerald gave a rating of “Overweight” to GLMD, setting the target price at $14 in the report published on January 30th of the previous year.
GLMD Trading at 3.29% from the 50-Day Moving Average
After a stumble in the market that brought GLMD to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -91.94% of loss for the given period.
Volatility was left at 11.88%, however, over the last 30 days, the volatility rate increased by 8.18%, as shares surge +31.45% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -17.06% lower at present.
During the last 5 trading sessions, GLMD rose by +49.29%, which changed the moving average for the period of 200-days by -42.60% in comparison to the 20-day moving average, which settled at $1.4475. In addition, Galmed Pharmaceuticals Ltd saw -39.84% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for GLMD
The total capital return value is set at -0.28. Equity return is now at value -49.77, with -42.80 for asset returns.
Currently, EBITDA for the company is -6.87 million with net debt to EBITDA at 0.75. The liquidity ratio also appears to be rather interesting for investors as it stands at 7.42.
Conclusion
In conclusion, Galmed Pharmaceuticals Ltd (GLMD) has seen mixed performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
